Home Biosimilar Antibodies Neuronal Signaling Beta Amyloid antibody Donanemab (Anti-Amyloid Beta) For research use only.
Not for use in humans.

Donanemab (Anti-Amyloid Beta)

Synonyms: LY3002813

Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody directed at an N‐terminal pyroglutamate amyloid beta (Aβ) epitope. Donanemab has the potential for early Alzheimer's disease research. MW : 145.36 KD.

Donanemab (Anti-Amyloid Beta)

Purity & Quality Control

≥99

Choose Selective Beta Amyloid Inhibitors

Biological Activity

Description Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody directed at an N‐terminal pyroglutamate amyloid beta (Aβ) epitope. Donanemab has the potential for early Alzheimer's disease research. MW : 145.36 KD.

Product Details

CAS No. 1931944-80-7
Molecular Weight 145.36
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100mMPro-Ac,20mMArg-Ac，pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Donanemab (Anti-Amyloid Beta) | Donanemab (Anti-Amyloid Beta) supplier | purchase Donanemab (Anti-Amyloid Beta) | Donanemab (Anti-Amyloid Beta) cost | Donanemab (Anti-Amyloid Beta) manufacturer | order Donanemab (Anti-Amyloid Beta) | Donanemab (Anti-Amyloid Beta) distributor